Since the Trust began in 1996 we have awarded over 37 grants. Our awards have ranged from a few hundred pounds to cover travel costs to £190,000 for the support of a programme grant. We support both basic science and applied medical research and strongly encourage collaboration between our researchers.
Key target areas for funding
The CGD Research Trust funds research into the cause, inheritance, diagnosis, management and treatment of CGD. It is willing to consider research applications of high quality, to address important scientific, clinical or social questions relating to CGD. The CGD Research Trust is committed to provide long-term funding in the following areas:
Other areas of particular priority are:
- Basic research concerning the structure and function of the enzyme NADPH
oxidase and identification of possible target pathways for therapeutic intervention.
Improvement of diagnosis for variant CGD.
Read More... - Mechanisms of inflammation leading to granuloma formation and inflammatory
bowel disease. The use of anti-inflammatory agents to treat inflammatory
problems in CGD.
Read More... - Causes of infection in CGD with particular reference to Aspergillus;
the mechanisms involved and improving methods of treatment.
Read More...
How Our Research Income is Spent
Our research investment is in a number of key areas that are important to finding a cure for CGD and tackling problems that affect CGD patients. This pie chart gives the proportion of our research income invested in different research subject areas (1996 - 2004).
IMPORTANT NOTE :
The information contained on this website is intended only as a guideline, not as a substitute for medical advice. Always consult your doctor if you or your child has any CGD symptoms or concerns.
© 2001-2005 The Chronic Granulomatous Disorder (CGD) Research Trust
Registered Charity No. 1003425 email:cgd@cgdrt.co.uk
The CGD Research Trust is a member of the Association of Medical Research Charities (AMRC), the Genetic Interest Group (GiG) and an associate member of the International Patient Organisation of Primary Immunodeficiencies (IPOPI)
Terms and Conditions | Privacy
